1. Koivisto VA, Felig P. Alterations in insulin absorption and in blood glucose control associated with varying insulin injection sites in diabetic patients. Ann Intern Med 1980; 92(1):59-61.

2. Calara F, Taylor K, Han J, et al. A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4). Clin Ther 2005; 27(2):210-215.

3. Vaag A, Handberg A, Lauritzen M, et al. Variation in absorption of NPH insulin due to intramuscular injection. Diabetes Care 1990; 13(1):74-76.

4. Galloway JA, Spradlin CT, Nelson RL, et al. Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various insulin mixtures. Diabetes Care 1981; 4(3):366-376.

5. Lindstrom T, Olsson PO, Arnqvist HJ. The use of human ultralente is limited by great intraindividual variability in overnight plasma insulin profiles. Scand J Clin Lab Invest 2000; 60(5):341-347.

6. Wikimedia Commons. File:Skin.jpg. Available at: wiki/Image:Skin.jpg.

7. Ji RC. Lymphatic endothelial cells, inflammatory lymphangiogenesis, and prospective players. Curr Med Chem 2007; 14(22):2359-2368.

8. Karpanen T, Alitalo K. Molecular biology and pathology of lymphangiogenesis. Annu Rev Pathol 2008; 3:367-397.

9. Wanner M, Avram M. An evidence-based assessment of treatments for cellulite. J Drugs Dermatol 2008; 7(4):341-345.

10. Brooks Y, Black DR, Coster DC, et al. Body mass index and percentage body fat as health indicators for young adults. Am J Health Behav 2007; 31(6):687-700.

11. Plopper GE. Extracellular matrix and cell junctions. In: Lewin B, Cassimeris L, Lingappa VR, et al., eds. Cells. Sudbury, MA: Jones & Bartlett, 2006:645-702.

12. Malavaki C, Mizumoto S, Karamanos N, et al. Recent advances in the structural study of functional chondroitin sulfate and dermatan sulfate in health and disease. Connect Tissue Res 2008; 49(3):133-139.

13. Peach RJ, Hollenbaugh D, Stamenkovic I, et al. Identification of hyaluronic acid binding sites in the extracellular domain of CD44. J Cell Biol 1993; 122(1):257-264.

14. Geutjes PJ, et al. From molecules to matrix: construction and evaluation of molec-ularly defined bioscaffolds. Adv Exp Med Biol 2006; 585:279-295.

15. Sugawara K, Tsuruta D, Ishii M, et al. Laminin-332 and -511 in skin. Exp Dermatol 2008; 17(6):473-480.

16. Lauria G, Lombardi R, Camozzi F, et al. Skin biopsy for the diagnosis of peripheral neuropathy. Histopathology 2009; 54(3):273-285.

17. Cohen JL. Understanding, avoiding, and managing dermal filler complications. Dermatol Surg 2008; 34(suppl 1):S92-S99.

18. Rizzoni D, Paiardi S, Rodella L, et al. Changes in extracellular matrix in subcutaneous small resistance arteries of patients with primary aldosteronism. J Clin Endocrinol Metab 2006; 91(7):2638-2642.

19. Wang D, Chabrashvili T, Borrego L, et al. Angiotensin II infusion alters vascular function in mouse resistance vessels: roles of O and endothelium. J Vasc Res 2006; 43(1):109-119.

20. Nelson HS. Allergen immunotherapy: where is it now? J Allergy Clin Immunol 2007; 119(4):769-779.

21. Komatsu N, Suga Y, Saijoh K, et al. Elevated human tissue kallikrein levels in the stratum corneum and serum of peeling skin syndrome-type B patients suggests an over-desquamation of corneocytes. J Invest Dermatol 2006; 126(10): 2338-2342.

22. Dean RA, Butler GS, Hamma-Kourbali Y, et al. Identification of candidate angio-genic inhibitors processed by matrix metalloproteinase 2 (MMP-2) in cell-based proteomic screens: disruption of vascular endothelial growth factor (VEGF)/hep-arin affin regulatory peptide (pleiotrophin) and VEGF/Connective tissue growth factor angiogenic inhibitory complexes by MMP-2 proteolysis. Mol Cell Biol 2007; 27(24):8454-8465.

23. Kainulainen V, Wang H, Schick C, et al. Syndecans, heparan sulfate proteoglycans, maintain the proteolytic balance of acute wound fluids. J Biol Chem 1998; 273(19): 11563-11569.

24. White FA, Wilson NM. Chemokines as pain mediators and modulators. Curr Opin Anaesthesiol 2008; 21(5):580-585.

25. Merad M, Hoffmann P, Ranheim E, et al., Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat Med 2004; 10(5):510-517.

26. Obhrai JS, Oberbarnscheidt M, Zhang N, et al. Langerhans cells are not required for efficient skin graft rejection. J Invest Dermatol 2008; 128(8):1950-1955.

27. Kwiek B, Peng WM, Allam JP, et al. Tacrolimus and TGF-beta act synergistically on the generation of Langerhans cells. J Allergy Clin Immunol 2008; 122(1):126-132, 132.e1.

28. Subramanyam M. Immunogenicity of biotherapeutics-an overview. J Immunotox-icol 2006; 3(3):151-156.

29. Ho LT, Lam HC, Wu MS, et al. A twelve month double-blind randomized study of the efficacy and immunogenicity of human and porcine insulins in non-insulin-dependent diabetics. Zhonghua Yi Xue Za Zhi (Taipei) 1991; 47(5):313-319.

30. Davis SN, Thompson CJ, Peak M, et al. Effects of human insulin on insulin binding antibody production in nondiabetic subjects. Diabetes Care 1992; 15(1):124-126.

31. Ebers GC, Dyment DA. Genetics of multiple sclerosis. Semin Neurol 1998; 18(3): 295-299.

32. Steis RG, Smith JW II, Urba WJ, et al. Resistance to recombinant interferon alfa-2a in hairy-cell leukemia associated with neutralizing anti-interferon antibodies. N Engl J Med 1988; 318(22):1409-1413.

33. Russo D, Candoni A, Zuffa E, et al. Neutralizing anti-interferon-alpha antibodies and response to treatment in patients with Ph+ chronic myeloid leukaemia sequentially treated with recombinant (alpha 2a) and lymphoblastoid interferonalpha. Br J Haematol 1996; 94(2):300-305.

34. Wadhwa M, Skog AL, Bird C, et al. Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF. Clin Cancer Res 1999; 5(6):1353-1361.

35. Macdougall IC. Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks. Nephrol Dial Transplant 2005; 20(suppl 4):iv9-iv15.

36. Kuter DJ. Future directions with platelet growth factors. Semin Hematol 2000; 37(2 suppl 4):41-49.

Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001; 98(12):3241-3248.

Basser RL, O'Flaherty E, Green M, et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood 2002; 99(7):2599-2602. Herzyk Dj. The immunogenicity of therapeutic cytokines. Curr Opin Mol Ther 2003; 5(2):167-171.

Dasgupta S, Bayry J, Andre; S, et al. Auditing protein therapeutics management by professional APCs: toward prevention of immune responses against therapeutic proteins. J Immunol 2008; 181(3):1609-1615.

Chenuaud P, Larcher T, Rabinowitz JE, et al. Autoimmune anemia in macaques following erythropoietin gene therapy. Blood 2004; 103(9):3303-3304. Bach JF. Infections and autoimmune diseases. J Autoimmun 2005; 25(suppl):74-80. Chen W, Antonenko S, Sederstrom JM, et al. Thrombopoietin cooperates with FLT3-ligand in the generation of plasmacytoid dendritic cell precursors from human hematopoietic progenitors. Blood 2004; 103(7):2547-2553.

Cines DB, McMillan R. Pathogenesis of chronic immune thrombocytopenic purpura. Curr Opin Hematol 2007; 14(5):511-514.

Swanson SJ. Immunogenicity issues in drug development. J Immunotoxicol 2006; 3(3):165-172.

Kelley DE, Thaete FL, Troost F, et al. Subdivisions of subcutaneous abdominal adipose tissue and insulin resistance. Am J Physiol Endocrinol Metab 2000; 278(5): E941-E948.

Bertuzzi F, Verzaro R, Provenzano V, et al. Brittle type 1 diabetes mellitus. Curr Med Chem 2007; 14(16):1739-1744.

Bookbinder LH, Hofer A, Haller MF, et al. A recombinant human enzyme for enhanced interstitial transport of therapeutics. J Control Release 2006; 114(2):230-241. Yocum RC, Kennard D, Heiner LS. Assessment and implication of the allergic sensitivity to a single dose of recombinant human hyaluronidase injection: a doubleblind, placebo-controlled clinical trial. J Infus Nurs 2007; 30(5):293-299. Gin H, Hanaire-Broutin H. Reproducibility and variability in the action of injected insulin. Diabetes Metab 2005; 31(1):7-13.

Daugherty AL, Cleland JL, Duenas EM, et al. Pharmacological modulation of the tissue response to implanted polylactic-co-glycolic acid microspheres. Eur J Pharm Biopharm 1997; 44(1637):89-102.

Kosaka H, Yoshimoto T, Yoshimoto T, et al. Interferon-gamma is a therapeutic target molecule for prevention of postoperative adhesion formation. Nat Med 2008; 14(4): 437-441.

Kaku K, Matsuda M, Urae A, et al. Pharmacokinetics and pharmacodynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteers. Diabetes Res Clin Pract 2000; 49(2-3):119-126.

Edelman ER, Pukac LA, Karnovsky MJ. Protamine and protamine-insulins exacerbate the vascular response to injury. J Clin Invest 1993; 91(5):2308-2313. Capobianchi MR, Mattana P, Mercuri F, et al. Acid lability is not an intrinsic property of interferon-alpha induced by HIV-infected cells. J Interferon Res 1992; 12(6):431-438.

Brange J. Galenics of Insulin: the Physico-Chemical and Pharmaceutical Aspects of Insulin and Insulin Preparations. New York: Springer-Verlag, 1987. Rottenberg DA, Ginos JZ, Kearfott KJ, et al. In vivo measurement of brain tumor pH using [11C]DMO and positron emission tomography. Ann Neurol 1985; 17(1):70-79. Ward KM, Balaban RS. Determination of pH using water protons and chemical exchange dependent saturation transfer (CEST). Magn Reson Med 2000; 44(5):799-802. Raghunand N, Zhang S, Sherry AD, et al. In vivo magnetic resonance imaging of tissue pH using a novel pH-sensitive contrast agent, GdDOTA-4AmP. Acad Radiol 2002; 9(suppl 2):S481-S483.

Gallagher FA, Zhang S, Sherry AD, et al. Magnetic resonance imaging of pH in vivo using hyperpolarized 13C-labelled bicarbonate. Nature 2008; 453(7197):940-943.

61. Chi EY, Krishnan S, Randolph TW, et al. Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation. Pharm Res 2003; 20(9):1325-1336.

62. Meredith SC. Protein denaturation and aggregation: cellular responses to denatured and aggregated proteins. Ann N Y Acad Sci 2005; 1066:181-221.

63. Kamerzell TJ, Middaugh CR. The complex inter-relationships between protein flexibility and stability. J Pharm Sci 2008; 97(9):3494-3517.

64. Pease LF III, Elliott JT, Tsai DH, et al. Determination of protein aggregation with differential mobility analysis: application to IgG antibody. Biotechnol Bioeng 2008; 101(6):1214-1222.

65. Brange J, Langkjoer L. Insulin structure and stability. Pharm Biotechnol 1993; 5: 315-350.

66. Peltonen L, Halila R, Ryhanen L. Enzymes converting procollagens to collagens. J Cell Biochem 1985; 28(1):15-21.

67. Fernandez-Busquets X, de Groot NS, Fernandez D, et al. Recent structural and computational insights into conformational diseases. Curr Med Chem 2008; 15(13): 1336-1349.

68. Uversky VN. Amyloidogenesis of natively unfolded proteins. Curr Alzheimer Res 2008; 5(3):260-287.

69. Avidan-Shpalter C, Gazit E. The early stages of amyloid formation: biophysical and structural characterization of human calcitonin pre-fibrillar assemblies. Amyloid 2006; 13(4):216-225.

70. Bellotti V, Mangione P, Stoppini M. Biological activity and pathological implications of misfolded proteins. Cell Mol Life Sci 1999; 55(6-7):977-991.

71. Trexler AJ, Nilsson MR. The formation of amyloid fibrils from proteins in the lysozyme family. Curr Protein Pept Sci 2007; 8(6):537-557.

72. Brouet JC, Clauvel JP, Danon F, et al. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 1974; 57(5):775-788.

73. Middaugh CR, Gerber-Jenson B, Hurvitz A, et al. Physicochemical characterization of six monoclonal cryoimmunoglobulins: possible basis for cold-dependent insolubility. Proc Natl Acad Sci U S A 1978; 75(7):3440-3444.

74. Baynes BM, Trout BL. Rational design of solution additives for the prevention of protein aggregation. Biophys J 2004; 87(3):1631-1639.

75. Baynes BM, Wang DI, Trout BL. Role of arginine in the stabilization of proteins against aggregation. Biochemistry 2005; 44(12):4919-4925.

76. Kertscher U, Bienert M, Krause E, et al. Spontaneous chemical degradation of substance P in the solid phase and in solution. Int J Pept Protein Res 1993; 41(3):207-211.

77. Cleland JL, Powell Mf, Shire SJ. The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. Crit Rev Ther Drug Carrier Syst 1993; 10(4):307-377.

78. Morgan PE, Sturgess AD, Davies MJ. Increased levels of serum protein oxidation and correlation with disease activity in systemic lupus erythematosus. Arthritis Rheum 2005; 52(7):2069-2079.

79. Wakankar AA, Borchardt RT, Eigenbrot C, et al. Aspartate isomerization in the complementarity-determining regions of two closely related monoclonal antibodies. Biochemistry 2007; 46(6):1534-1544.

80. Huang L, Lu J, Wroblewski VJ, et al. In vivo deamidation characterization of monoclonal antibody by LC/MS/MS. Anal Chem 2005; 77(5):1432-1439.

81. Robinson NE, Robinson AB. Deamidation of human proteins. Proc Natl Acad Sci USA 2001; 98(22):12409-12413.

82. Robinson NE, Robinson AB. Molecular clocks. Proc Natl Acad Sci U S A 2001; 98(3): 944-949.

83. Lindner H, Helliger W. Age-dependent deamidation of asparagine residues in proteins. Exp Gerontol 2001; 36(9):1551-1563.

84. Watanabe A, Takio K, Ihara Y. Deamidation and isoaspartate formation in smeared tau in paired helical filaments. Unusual properties of the microtubule-binding domain of tau. J Biol Chem 1999; 274(11):7368-7378.

Schey KL, Little M, Fowler JG, et al. Characterization of human lens major intrinsic protein structure. Invest Ophthalmol Vis Sci 2000; 41(1):175-182. Tyagi SC, Kumar S, Katwa L. Differential regulation of extracellular matrix metal-loproteinase and tissue inhibitor by heparin and cholesterol in fibroblast cells. J Mol Cell Cardiol 1997; 29(1):391-404.

Wygrecka M, Jablonska E, Guenther A, et al. Current view on alveolar coagulation and fibrinolysis in acute inflammatory and chronic interstitial lung diseases. Thromb Haemost 2008; 99(3):494-501.

Wahl LM, Corcoran ML. Regulation of monocyte/macrophage metalloproteinase production by cytokines. J Periodontol 1993; 64(5 suppl):467-473. Kahari VM, Saarialho-Kere U. Matrix metalloproteinases in skin. Exp Dermatol 1997; 6(5):199-213.

Riley KN, Herman IM. Collagenase promotes the cellular responses to injury and wound healing in vivo. J Burns Wounds 2005; 4:e8.

Eppler SM, Combs DL, Henry TD, et al. A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin Pharmacol Ther 2002; 72(1):20-32. Hollier B, Harkin DG, Leavesley D, et al. Responses of keratinocytes to substrate-bound vitronectin: growth factor complexes. Exp Cell Res 2005; 305(1):221-232. Stachowska-Pietka J, Waniewski J, Flessner MF, et al. A distributed model of bidirectional protein transport during peritoneal fluid absorption. Adv Perit Dial 2007; 23:23-27.

Haupt MT. The use of crystalloidal and colloidal solutions for volume replacement in hypovolemic shock. Crit Rev Clin Lab Sci 1989; 27(1):1-26.

Tong RT, Boucher Y, Kozin SV, et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004; 64(11):3731-3736. Pluen A, Boucher Y, Ramanujan S, et al. Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc Natl Acad Sci U S A 2001; 98(8):4628-4633.

Flessner MF. The role of extracellular matrix in transperitoneal transport of water and solutes. Perit Dial Int 2001; 21(suppl 3):S24-S29.

Schweitzer AD, Rakesh V, Revskaya E, et al. Computational model predicts effective delivery of 188-Re-labeled melanin-binding antibody to metastatic melanoma tumors with wide range of melanin concentrations. Melanoma Res 2007; 17(5):291-303. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008; 359(9): 938-949.

Gurtner GC, Werner S, Barrandon Y, et al. Wound repair and regeneration. Nature 2008; 453(7193):314-321.

Swart PJ, Beljaars L, Kuipers ME, et al. Homing of negatively charged albumins to the lymphatic system: general implications for drug targeting to peripheral tissues and viral reservoirs. Biochem Pharmacol 1999; 58(9):1425-1435. Andersen JT, Dee Qian J, Sandlie I. The conserved histidine 166 residue of the human neonatal Fc receptor heavy chain is critical for the pH-dependent binding to albumin. Eur J Immunol 2006; 36(11):3044-3051.

Kim J, Bronson CL, Hayton WL, et al. Albumin turnover: FcRn-mediated recycling saves as much albumin from degradation as the liver produces. Am J Physiol Gastrointest Liver Physiol 2006; 290(2):G352-G360.

Kurtzhals P. How to achieve a predictable basal insulin? Diabetes Metab 2005; 31(4 pt 2):4S25-4S33.

Chuang VT, Kragh-Hansen U, Otagiri M. Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm Res 2002; 19(5):569-577. Glickson JD, Lund-Katz S, Zhou R, et al. Lipoprotein nanoplatform for targeted delivery of diagnostic and therapeutic agents. Mol Imaging 2008; 7(2):101-110. Dumont JA, Low SC, Peters RT, et al. Monomeric Fc fusions: impact on pharma-cokinetic and biological activity of protein therapeutics. BioDrugs 2006; 20(3): 151-160.

108. Jazayeri JA, Carroll GJ. Fc-based cytokines: prospects for engineering superior therapeutics. BioDrugs 2008; 22(1):11-26.

109. Sharma R, Wendt JA, Rasmussen JC, et al. New horizons for imaging lymphatic function. Ann N Y Acad Sci 2008; 1131:13-36.

110. Dani B, Platz R, Tzannis ST. High concentration formulation feasibility of human immunoglubulin G for subcutaneous administration. J Pharm Sci 2007; 96(6): 1504-1517.

111. Basu SK, Govardhan CP, Jung CW, et al. Protein crystals for the delivery of bio-pharmaceuticals. Expert Opin Biol Ther 2004; 4(3):301-317.

112. Yang MX, Shenoy B, Disttler M, et al. Crystalline monoclonal antibodies for subcutaneous delivery. Proc Natl Acad Sci U S A 2003; 100(12):6934-6939.

113. Govardhan C, Khalaf N, Jung CW, et al. Novel long-acting crystal formulation of human growth hormone. Pharm Res 2005; 22(9):1461-1470.

114. Alam M, Dover JS. Management of complications and sequelae with temporary injectable fillers. Plast Reconstr Surg 2007; 120(6 suppl):98S-105S.

115. Nicolas JF, Guy B. Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev Vaccines 2008; 7(8):1201-1214.

116. Soares AP, Scriba TJ, Joseph S, et al. Bacillus Calmette-Guerin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles. J Immunol 2008; 180(5):3569-3577.

117. Schultze V, D'Agosto V, Wack A, et al. Safety of MF59 adjuvant. Vaccine 2008; 26(26):3209-3222.

118. Roy P, Noad R. Virus-like particles as a vaccine delivery system: myths and facts. Hum Vaccin 2008; 4(1):5-12.

119. Wallace AM, Hoh CK, Darrah DD, et al. Sentinel lymph node mapping of breast cancer via intradermal administration of Lymphoseek. Nucl Med Biol 2007; 34(7): 849-853.

120. Nagy G, Emody L, Pal T. Strategies for the development of vaccines conferring broad-spectrum protection. Int J Med Microbiol 2008; 298(5-6):379-395.

121. Chabalgoity JA. Paving the way for the introduction of new vaccines into developing countries. Expert Rev Vaccines 2005; 4(2):147-150.

122. Lambert PH, Laurent PE. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine 2008; 26(26):3197-3208.

123. Liu L, Zhou X, Shi J, et al. Toll-like receptor-9 induced by physical trauma mediates release of cytokines following exposure to CpG motif in mouse skin. Immunology 2003; 110(3):341-347.

124. Hui SW. Overview of drug delivery and alternative methods to electroporation. Methods Mol Biol 2008; 423:91-107.

125. Vandervoort J, Ludwig A. Microneedles for transdermal drug delivery: a minireview. Front Biosci 2008; 13:1711-1715.

Local Tissue Responses to Polymer Implants Affecting Pharmacokinetics, Pharmacodynamics, and Metabolism of Proteins and Peptides

James M. Anderson and William G. Brodbeck

Institute of Pathology, Case Western Reserve University, Cleveland, Ohio, U.S.A.

51 Ways to Reduce Allergies

51 Ways to Reduce Allergies

Do you hate the spring? Do you run at the site of a dog or cat? Do you carry around tissues wherever you go? Youre not alone. 51 Ways to Reduce Allergies can help. Find all these tips and more Start putting those tissues away. Get Your Copy Of 51 Ways to Reduce Allergies Today.

Get My Free Ebook

Post a comment